NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network
A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague.
Kadima, renowned for its integration of advanced clinical care and research, particularly in psychedelic medications and transcranial magnetic stimulation (TMS), will now anchor HOPE's ambitious nationwide rollout. The acquisition is expected to immediately boost both revenue and EBITDA, bringing profitability to the group.
Dr. David Feifel, Kadima's founder and a recognized leader in interventional psychiatry, will join HOPE Therapeutics as Chief Medical Innovation Officer. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)'s broader pipeline includes investigational drugs for suicidal bipolar depression and chronic pain.
HOPE Therapeutics aims to acquire 30 clinics by the end of 2025, with a projected $100 million in annual revenue. Kadima's comprehensive treatment offerings for suicidal depression, PTSD, and other mental health conditions set a new standard for the company's expanding footprint in psychiatric care.
While we acknowledge the potential of NRXP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NRXP and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
If I Could Only Buy and Hold a Single Stock, This Would Be It
Key Points Amazon and its management team are experienced with trying new things. Every success or failure, however, is a learning experience. History has shown that companies that foster innovation and don't punish failure tend to thrive, while those that fear it or are unwilling to adapt often struggle. 10 stocks we like better than Amazon › Investors can own as many individual stocks as they want and can afford. Sometimes, though, hypothetically imagining that you're limited to just one can be enlightening. That thought experiment forces you to rate and rank the strengths and flaws of every investment candidate on your radar. This process can -- in a good way -- really help you narrow down your list to a small handful of top options. Or one. And I know exactly which one that would be for me. If I could only buy and hold a single stock, it would be Amazon (NASDAQ: AMZN). Here's why. What Amazon really is You very likely already know the company. Amazon is, of course, the king of North American e-commerce, accounting for nearly 40% of the market's total revenue, according to research by Digital Commerce 360. It's doing alright overseas, too. Then there's its cloud computing arm, Amazon Web Services, which provides a relatively small portion of its revenue, but is responsible for nearly 60% of the company's operating profits. However, these numbers still don't even come close to telling the whole story. Amazon also manages an on-demand video platform (Prime), owns grocery store chain Whole Foods Markets, does delivery work for other online retailers, and sells prescription pharmaceuticals through its Pillpack arm. It also monetizes its online mall by allowing its sellers to pay for more prominent promotion, creating an advertising business that generated $15.7 billion in revenue last quarter alone, by the way. On top of all that, it owns websites and Twitch, and is the parent to camera-doorbell brand Ring. There's a method to the madness behind these seemingly disparate lines of business, though. While most companies focus on doing one or two things extremely well, Amazon has orchestrated several different lines of business, each of which fuels another, and each of which is fueled by another. The result is a mesh of different profit centers that ultimately funnels consumers and corporations into Amazon's ecosystem. Yes, it's complicated, but yes, Amazon can handle it. That's not quite the only reason I'd be willing to make Amazon my one and only stock holding, though. Jeff Bezos started it Companies founded or grown by bigger-than-life leaders can make for potentially problematic investments. It's just difficult to determine if it's the company that's something special, or the person. If it's the person, what happens when that individual is no longer at the helm? Case in point: General Electric was never quite the same after Jack Welch stepped down as CEO in 2001. Steve Jobs was also nearly synonymous with Apple until he passed the torch to Tim Cook in 2011. While Cook has been a solid successor, he's arguably not quite as captivating or magical as his predecessor. Neither is Apple under him. Still, most high-profile chief executives -- and founders in particular -- manage to leave their mark on their company's culture. That imprint remains part of the organization's ethos even in their absence. While current Amazon CEO Andy Jassy is no Jeff Bezos, for instance, Bezos' philosophy remains. Take, for example, the company's willingness to experiment. As Bezos noted in his 2016 letter to Amazon's shareholders, "Most large organizations embrace the idea of invention, but are not willing to suffer the string of failed experiments necessary to get there." That does not describe Amazon, though. Bezos made a point of fostering a "fail fast, fail often" work culture that did end up producing some failures, such as the Fire smartphone. Such experiments, however, also led to the creation of Amazon Web Services and Amazon Prime, the latter of which has been a massive growth driver for the company. Now Jassy is blending his own mindset with Bezos'. As he said while discussing the company's core 16 leadership principles, "At Amazon, you are not just empowered to speak up if you think we're doing something wrong for customers of the business. You're expected to do so, regardless of level." It works. Amazon is an even bigger company now than it was when Bezos stepped down as CEO. Don't underestimate the power of a willingness to innovate Many investors will point out that a healthy corporate culture doesn't pay the bills. I agree. At some point, to thrive, every company must sell its products or services profitably. Amazon is no exception. History has shown, however, that companies with corporate cultures that encourage innovation and don't punish failure tend to prosper while organizations that are cautiously and defensively managed often struggle. Compare Alphabet today to post-Welch GE, for instance. The manufacturing conglomerate ultimately hit a wall after years of obscuring the true depth of its insurance arm's liabilities from a management team that might have been able to fix them (although the company didn't exactly embrace the advent of the digital age either). Or compare Blockbuster to Netflix. The once-giant video rental chain infamously had a chance to buy the latter for a mere $50 million back in 2000. At the time, Blockbuster was doing on the order of $4 billion worth of business per year, and could have easily purchased Netflix, if only to take its budding competitor out of the market. But it didn't. In its defense, Blockbuster's decision at the time wasn't quite the obvious misstep it seems in retrospect. Remember, Netflix wasn't yet streaming then. It was still only renting DVDs by mail. Given Blockbuster's dominance of the brick-and-mortar movie rental business back in 2000, the logistics behind this new kind of movie rental business model understandably didn't make sense to the now-defunct company. In many regards, though, that story underscores the underlying theme here in an even more effective way. Even if Blockbuster didn't want Netflix, Blockbuster certainly could have leveraged its own powerful brand to become a streaming powerhouse. Likewise, if not Netflix, some other enterprising outfit would have eventually launched the streaming-video business. Netflix was simply the outfit that tried the idea out first, knowing when it did so that it might end in failure. So for my money, I'll bet on a company that is experienced with managing experiments' successes as well as failures -- and learning from both -- to evolve and thrive. That said, it certainly doesn't hurt the bullish argument that Amazon has the financial flexibility to experiment. With its $2.5 trillion market cap, it does more than $600 billion worth of business per year, and turns about $60 billion of that into net income. Meanwhile, it's only sitting on a little over $80 billion in long-term debt. It's much easier not to fear failure when you can actually afford to take big swings, miss, and try again. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 James Brumley has positions in Alphabet. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, and Netflix. The Motley Fool recommends GE Aerospace. The Motley Fool has a disclosure policy. If I Could Only Buy and Hold a Single Stock, This Would Be It was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?
GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth Novo Nordisk (NVO). In a press release this morning, the Nasdaq-listed firm said 'all strengths of Ozempic and Wegovy pens are now available to eligible self-paying patients for $499-per-month through GoodRx.' More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! GoodRx stock has slightly outperformed in 2025, up just over 12% in the year to date. How Novo Deal May Help GoodRx Stock Teaming up with Novo Nordisk is a major win for GDRX shares because it positions the healthcare platform at the center of the booming GLP-1 weight-loss and diabetes drug market. Offering Ozempic and Wegovy at a flat $499 per month to self-paying customers helps GoodRx expand access to high-demand medications while reinforcing its value proposition as a cost-saving platform. Over time, this could drive user growth, boost engagement, and attract new pharmacy and pharma partnerships as well. In short, with GLP-1 drugs making headlines and consumer interest soaring, GoodRx stock is now tied to one of the most lucrative trends in healthcare. Why BofA Remains Bearish on GDRX Shares Despite the aforementioned positives, Bank of America analyst Allen Lutz says the Novo Nordisk deal is far from a sufficient reason to load up on GoodRx shares at current levels. In a note to clients, Lutz argued widespread pharmacy closures and changing reimbursement policy could make it difficult for GDRX stock to retain momentum in the days ahead. On Monday, the BofA analyst maintained his 'Underperform' rating and $3.40 price target on the healthcare platform, indicating potential downside of more than 30% from here. Wall Street Disagrees with BofA on GoodRx Investors should note, however, that Bank of America Securities is among the more bearish Wall Street firms on GoodRx stock in 2025. According to Barchart, the consensus rating on GDRX shares remains at 'Moderate Buy' with the mean target of $5.49 indicating potential 'upside' of another 5% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Dick's Sporting Goods (DKS) Increases Despite Market Slip: Here's What You Need to Know
Dick's Sporting Goods (DKS) closed the most recent trading day at $227.57, moving +1.87% from the previous trading session. This change outpaced the S&P 500's 0.59% loss on the day. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, lost 1.46%. Coming into today, shares of the sporting goods retailer had gained 3.69% in the past month. In that same time, the Retail-Wholesale sector gained 3.3%, while the S&P 500 gained 2.49%. The investment community will be closely monitoring the performance of Dick's Sporting Goods in its forthcoming earnings report. The company is scheduled to release its earnings on August 28, 2025. On that day, Dick's Sporting Goods is projected to report earnings of $4.29 per share, which would represent a year-over-year decline of 1.83%. Meanwhile, the latest consensus estimate predicts the revenue to be $3.6 billion, indicating a 3.57% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of $14.38 per share and a revenue of $13.9 billion, demonstrating changes of +2.35% and +3.37%, respectively, from the preceding year. Any recent changes to analyst estimates for Dick's Sporting Goods should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% higher. Dick's Sporting Goods is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, Dick's Sporting Goods currently has a Forward P/E ratio of 15.53. This valuation marks no noticeable deviation compared to its industry average Forward P/E of 15.53. We can additionally observe that DKS currently boasts a PEG ratio of 3.19. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Retail - Miscellaneous was holding an average PEG ratio of 3.11 at yesterday's closing price. The Retail - Miscellaneous industry is part of the Retail-Wholesale sector. This industry, currently bearing a Zacks Industry Rank of 157, finds itself in the bottom 37% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DICK'S Sporting Goods, Inc. (DKS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
